The role of intermittent androgen deprivation in prostate cancer (Q36896020)

16 August 2017

1 reference

title

The role of intermittent androgen deprivation in prostate cancer (English)

1 reference

16 August 2017

1 reference

1

Laurent Boccon-Gibod

1 reference

16 August 2017

Peter Hammerer

2

1 reference

16 August 2017

Stephan Madersbacher

3

1 reference

16 August 2017

Nicolas Mottet

4

1 reference

16 August 2017

Tommaso Prayer-Galetti

5

1 reference

16 August 2017

Ulf Tunn

6

1 reference

16 August 2017

language of work or name

1 reference

23 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

100

1 reference

16 August 2017

4

1 reference

16 August 2017

738-743

1 reference

Complementary and alternative therapies for advanced prostate cancer

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen suppression in the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07053.X

10.1111/J.1464-410X.2007.07053.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference